5//SEC Filing
Protea Biosciences Group, Inc. 5
Accession 0001144204-14-008740
CIK 0001335103operating
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 7:25 PM ET
Size
19.0 KB
Accession
0001144204-14-008740
Insider Transaction Report
Form 5
SEGAL SCOTT
Director
Transactions
- Purchase
Common Stock, par value $0.0001 per share ("Common Stock")
2011-12-27$2.00/sh+50,000$100,000→ 1,569,123 total - Purchase
Common Stock
2013-07-23$0.50/sh+388,038$194,019→ 1,957,161 total - Purchase
Warrant
2011-12-27+25,000→ 933,334 totalExercise: $2.25From: 2011-12-27Exp: 2016-12-27→ Common Stock (25,000 underlying) - Purchase
Warrant
2013-07-23+291,029→ 1,224,363 totalExercise: $1.10From: 2013-06-30Exp: 2018-07-23→ Common Stock (291,029 underlying) - Conversion
Convertible Notes
2013-07-23$194019.00/sh−388,038$75,286,744,722→ 1,224,363 totalExercise: $0.50From: 2013-07-23Exp: 2013-07-23→ Common Stock - Award
Stock Option
2008-05-30$150000.00/sh+100,000$15,000,000,000→ 1,324,363 totalExercise: $1.50From: 2008-05-30Exp: 2018-05-30→ Common Stock (100,000 underlying) - Award
Stock Option
2013-03-22$120313.00/sh+218,750$26,318,468,750→ 1,209,779 totalExercise: $0.55From: 2013-03-22Exp: 2023-03-22→ Common Stock (218,750 underlying)
Footnotes (5)
- [F1]On December 27, 2011 (the "December Closing Date"), the Company issued to Scott Segal (the "Reporting Person") one unit (the "Unit"), consisting of 50,000 shares of the Company's common stock, at a price of $2.00 per share, and a warrant (the "Warrant") to purchase 25,000 shares of Common Stock at an exercise price of $2.25 per share.
- [F2]On April 16, 2012, the Company issued a Convertible Promissory Note to the Reporting Person in the aggregate principal amount of $100,000. On September 25, 2012 the Company issued a convertible promissory note to the Reporting Person in the aggregate principal amount of $75,000. On March 22, 2013, the Company approved a reduction in the conversion price to $0.50 per share. On June 30, 2013, pursuant to the terms and conditions of a Conversion Agreement, dated June 18, 2013, outstanding principal and interest equal to $194,019 was converted into 388,038 shares of common stock.
- [F3]Pursuant to the Conversion Agreement, upon conversion of the April Note and September Note, the Company agreed to issue a warrant to purchase 75% of the number of shares into which the notes are convertible.
- [F4]Represents shares vested as of February 10, 2014.
- [F5]Reflects the expiration of previously reported warrants to purchase 333,334 shares of common stock held by the Reporting Person.
Documents
Issuer
Protea Biosciences Group, Inc.
CIK 0001335103
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001335103
Filing Metadata
- Form type
- 5
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 7:25 PM ET
- Size
- 19.0 KB